HISTOINDEX PTE. LTD
{{company.company_channel.channel_name}}
Media Room
{{company.company_name_local}}
{{company.company_channel.channel_name}}
Company Profile
Media Room
HistoIndex Presents Advancements in AI-powered Stain-free Tissue Imaging for NASH Clinical Trials at EASL Congress 2023 2023-06-21 20:00
HistoIndex SHG/TPE imaging and AI-based technology reveals dose-dependent effectiveness of Tropifexor for NASH patients in Nature Medicine 2023-06-15 20:00
TANDEM study shows potential of HistoIndex SHG/TPE imaging and AI-based technology in evaluating the effects of combination therapy for NASH 2023-06-15 20:00
HistoIndex embarks on partnership with VCU's Stravitz-Sanyal Institute for Liver Disease and Metabolic Health in the study of liver diseases 2023-04-10 19:00
Appointment of Dr. David John Jeans CBE as HistoIndex's Non-Executive Chairman 2023-01-10 13:01
HistoIndex Stain-free AI-DP Reveals Treatment-induced Zonal Regression of Fibrosis Colocalized with Reduction in Steatosis & Hepatocyte Ballooning in FLIGHT-FXR NASH Clinical Trial 2022-07-29 19:00
HistoIndex Welcomes Life Sciences and MedTech Visionary, David John Jeans CBE, to Board of Directors 2022-05-18 19:00
HistoIndex and Global Liver Experts Advance Stain-free AI Quantification of Hepatocyte Ballooning as a Reproducible Approach and Potential Endpoint for NASH Clinical Trials 2022-04-27 17:34
Biobot Surgical signs MOU with BEBIG Medical to collaborate on a robotic-guided prostate brachytherapy solution 2022-03-11 13:00
Biobot Surgical signs MOU with BEBIG Medical to collaborate on a robotic-guided prostate brachytherapy solution 2022-03-11 13:00
New Robotic Assisted Transperineal Needle-Guidance System for Prostate Biopsy and Cancer Ablations Received U.S FDA 510(k) Clearance 2022-03-05 20:00
HistoIndex and Galecto to Collaborate on Galecto's Phase 2a MYLOX-1 Clinical Trial to Advance Myelofibrosis Assessment with AI-based Stain-free Digital Pathology 2021-10-20 18:00
HistoIndex's Stain-free AI-based Digital Pathology Incorporated as Secondary and Exploratory Efficacy Endpoints in Sagimet's NASH FASCINATE-2 Phase 2b Clinical Trial 2021-08-18 18:00
HistoIndex's AI-Based Digital Pathology Indicates Concomitant Histological Improvements in Liver Fat and Fibrosis in Nonalcoholic Steatohepatitis (NASH) Patients Treated with Tropifexor Compared with Placebo 2021-06-25 18:30
HistoIndex Explores the Clinical Utility of Stain-free AI Digital Pathology Platform in 388 Patients with Triple-Negative Breast Cancer (TNBC) 2021-01-25 06:00
HistoIndex and Consortium Partners Awarded S$1.2M for the Development of AI-based Diagnostics Tool in the Identification of High-Risk Nonalcoholic Fatty Liver Disease Population 2020-12-15 12:00
HistoIndex's AI-Based Platform Demonstrates Zonal Quantification and Histological Characterization of Fibrosis Improvements in Patients With Nonalcoholic Steatohepatitis (NASH) 2020-11-18 20:00
Endofotonics Raises S$12 million in Series B Funding for the Commercialization of its AI Powered Medical Device to Support Clinicians in the Real Time Detection of Early Stomach Cancer 2020-05-29 07:00
HistoIndex's AI-based Digital Pathology Platform: A Validated Quantification Tool Recommended in the Guidelines for the Prevention and Treatment of Chronic Hepatitis B in China 2020-05-25 06:00
qFIBS Demonstrates Suitability for Nonalcoholic Steatohepatitis (NASH) Assessment in Clinical Trials and Patient Care with Full Quantification of All Crucial Histopathological Features 2019-11-11 13:28
1 2